A panel of international experts has proposed dropping the term ‘minimal’ residual disease alongside other recommendations to standardise nomenclature and assessment of measurable residual disease (MRD) as an indicator of disease burden in chronic lymphocytic leukaemia (CLL), in light of emerging treatments able to achieve deep remission. In an article published in Leukaemia, a research ...
MRD is ‘measurable’ not ‘minimal’ residual disease: new consensus recommendations
By Selina Wellbelove
9 Dec 2021